Table_1_Association between oxidative balance score and sarcopenia in US adults: NHANES 2011–2018.XLSX

BackgroundSarcopenia, a condition characterized by diminished skeletal muscle mass, strength, and function, accompanied by inflammation and oxidative stress, remains an area of limited exploration concerning its correlation with the Oxidative Balance Score (OBS).MethodsLeveraging data from the 2011–2018 National Health and Nutrition Examination Survey (NHANES), we meticulously examined 16 dietary and four lifestyle factors to derive the OBS. Adjusting appendicular skeletal muscle mass (ASM) by body mass index (BMI) served as the designated marker for sarcopenia. To scrutinize the association between OBS and sarcopenia, we conducted weighted logistic regression and engaged in sensitivity analysis. Furthermore, we implemented subgroup analysis and interaction tests to gain comprehensive insights into the relationship across diverse populations.ResultsIn a sample comprising 6,677 individuals aged 20–59, logistic regression illuminated a negative association between OBS and sarcopenia [OR = 0.942 (0.920, 0.964), p ConclusionOur study posits a perceptible link between OBS and the prevalence of sarcopenia among American adults.</p

Spatial-Potential-Color-Resolved Bipolar Electrode Electrochemiluminescence Biosensor Using a CuMoOx Electrocatalyst for the Simultaneous Detection and Imaging of Tetracycline and Lincomycin

A spatial-potential-color-resolved bipolar electrode electrochemiluminescence biosensor (BPE-ECL) using a CuMoOx electrocatalyst was constructed for the simultaneous detection and imaging of tetracycline (TET) and lincomycin (LIN). HOF-101 emitted peacock blue light under positive potential scanning, and CdSe quantum dots (QDs) emitted green light under negative potential scanning. CuMoOx could catalyze the electrochemical reduction of H2O2 to greatly increase the Faradic current of BPE and realize the ECL signal amplification. In channel 1, CuMoOx-Aptamer II (TET) probes were introduced into the BPE hole (left groove A) by the dual aptamer sandwich method of TET. During positive potential scanning, the polarity of BPE (left groove A) was negative, resulting in the electrochemical reduction of H2O2 catalyzed by CuMoOx, and the ECL signal of HOF-101 was enhanced for detecting TET. In channel 2, CuMoOx-Aptamer (LIN) probes were adsorbed on the MXene of the driving electrode (DVE) hole (left groove B) by hydrogen-bonding and metal-chelating interactions. LIN bound with its aptamers, causing CuMoOx to fall off. During negative potential scanning, the polarity of DVE (left groove B) was negative and the Faradic current decreased. The ECL signal of CdSe QDs was reduced for detecting LIN. Furthermore, a portable mobile phone imaging platform was built for the colorimetric (CL) detection of TET and LIN. Thus, the multiple mode-resolved detection of TET and LIN could be realized simultaneously with only one potential scan, which greatly improved detection accuracy and efficiency. This study opened a new technology of BPE-ECL sensor application and is expected to shine in microchips and point-of-care testing (POCT)

Chylomicron formation promotes intestinal absorption of full-length, antigenic OVA.

<p>Fasted mice were gavaged with 0.2 ml emulsions as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0008442#pone-0008442-g001" target="_blank">Figure 1</a>, except that ¹²⁵I-OVA was replaced with 25 mg OVA. Blood samples were obtained from the submandibular vein at indicated time points and analyzed for OVA by Western blotting.</p

Chylomicron formation promotes intestinal OVA absorption.

<p>Fasted mice were gavaged with a dispersion of 0.05 ml ¹²⁵I-labeled OVA (black bars) in PBS plus 0.15 ml of either LCT, MCT, or LCT plus 6 µl of Pluronic L-81 (Pl-81). Radioactivity in the entire plasma per mouse (top panel) and in pooled MLN per mouse (bottom panel) was measured 90 minutes later. Another group of mice was gavaged with identical solutions, except that ¹²⁵I-OVA was replaced with [³H]-retinol (white bars). Shown are averages±S.D. of 4 mice per experimental group; * indicates statistically significant differences between feeding groups (P<0.05; ANOVA, Bonferroni's posthoc analysis). The figure shows a representative outcome of two repeats.</p

Image_1_Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study.jpeg

BackgroundFor a majority of patients with metastatic colorectal cancer (mCRC) with MS stable (MSS) or mismatch repair proficient (pMMR), the role of immunotherapy is undetermined. This study investigated the efficacy and safety of camrelizumab when added to XELOX chemotherapy plus bevacizumab or regorafenib as first-line therapy for mCRC.Materials and MethodsMedical records of mCRC patients who received camrelizumab and XELOX plus bevacizumab or regorafenib at the First Hospital of Quanzhou Affiliated to Fujian Medical University between June 1, 2019, and April 30, 2021, were retrospectively collected. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and side effects of the drug were recorded and reviewed.ResultsTwenty-five eligible patients received combination therapy, including bevacizumab in 19 patients and regorafenib in 6. Twenty-one patients had pMMR/MSS and one MSI-H. Of the 25 patients who could be evaluated for efficacy, 18 (72%) achieved PR, 6 (24%) achieved SD, and 1 (4%) achieved PD. The ORR and DCR were 72% (18/25) and 96% (24/25), respectively. The median progression-free survival (PFS) was 11.2 months (95% CI 8.9–13.9), and OS had not yet been reached. The combination regimen of regorafenib in six (24%) patients was unassociated with treatment outcomes. Most AEs were either grade 1 or 2, and treatment-related grade 3 toxicities were observed in 8/25 (32%) patients.ConclusionCamrelizumab combined with XELOX plus bevacizumab or regorafenib was feasible, producing high rates of responses as first-line therapy in unselected Chinese patients with MSS mCRC. The toxicities were generally tolerable and manageable. Prospective randomized trials with large sample sizes are needed to evaluate these findings.</p

Expression of CD3 and osteopontin in mesenteric fat in response to dietary antigen.

<p>Naïve mice (A–C) or OVA-sensitized mice (D–F) were fed 1% egg-white diets for two weeks, and mesenteric adipose tissue was stained for CD3 (Panels A,B, D, E; red signal) or osteopontin (C, F; brown signal). Nuclei in A,B,D and E were stained blue with DAPI.</p

Chylomicron formation promotes systemic dissemination and antigen presentation of dietary antigen.

<p>Naïve BALB/C mice were injected with 2.5×10⁶ CFSE labeled T cells from DO11.10 TCR transgenic mice. After 24 h, the mice were fasted (4 h) and gavaged with OVA (25 mg) in 0.2 ml PBS or 25 mg OVA in 0.05 ml PBS+0.15 ml of either MCT, LCT, or LCT plus Pl-81. Mice were then fasted for an additional 6 h. Three days later, inguinal LN cells were isolated, stained with anti-CD4 and KJ1-26 (TCR clonotypic antibody), and analyzed by flow cytometry. Histograms show representative CFSE dilution profiles of gated CD4+, KJ1-26+ T cells as a measure of cell division. The % of cells under markers M1 and M2 represent cells which have not or have undergone cell division respectively. Each panel represents a typical result of three experimental repeats.</p

CD4 T-cell accumulation in mesenteric adipose tissue of OVA-fed, OVA sensitized mice.

<p>Naïve or OVA-sensitized C57Bl/6 mice were fed 1% OVA-containing high-fat diets for 14 weeks and SVF cells from their mesenteric adipose tissue were analyzed by flow cytometry. Two representative scatter plots are shown (A). The bar graph (B) shows the average percentage CD4 or CD8 T-lymphocytes ± S.D. (n = 5 mice per group). The asterisk (*) indicates statistically significant differences (P<0.05; Student's T-test).</p

Plasma chylomicrons transport dietary OVA.

<p>Fasted mice were gavaged with 0.2 ml LCT-containing emulsions also containing 25 mg OVA. Plasma was isolated 1 h later, and 55 µl were fractionated via FPLC. The grey line of the chromatogram shows the elution profile of a mouse injected i.p. with Poloxamer P-407 1 h prior to gavage to inhibit chylomicron clearance, which caused a milky plasma appearance (inset) and a greatly increased first peak. The solid line shows the elution profile of a mouse not previously injected with Poloxamer P-407. The fractions of this mouse, indicated by the vertical separators, were subjected to immunoprecipitation for detection of OVA (lower panel).The experiment was repeated three times with similar outcomes.</p

Inflammatory immune responses to gut antigen in mesenteric adipose tissue impair glucose tolerance.

<p>OVA-sensitized (solid lines and symbols) or naïve (dashed lines, open symbols) mice were put on 1% OVA-containing high-fat diets for the indicated duration, and a glucose tolerance test was then performed on fasted mice. Glucose clearance was significantly impaired in sensitized BALB/c mice after 10 and 14 weeks (linear mixed model test for identical trajectories) and trended to significantly decrease in C57Bl/6 mice after 14 weeks.</p